Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Will Validate siRNA Delivery Technology For MDRNA In Shanghai Innovation Center

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Bothell, Washington-headquartered MDRNA announced recently that the company will collaborate with AstraZeneca to validate MDRNA's small interfering RNA (siRNA) technology for systemic delivery in hepatocellular carcinoma, one of the company's preclinical oncology programs

You may also be interested in...

China Leads Pharmaceutical Growth In 2009: Asia Pharma R&D Leaders

SHANGHAI - While China's most influential meeting - the eleventh National People's Congress of China - prepares to open its third session in Beijng March 5, pharma R&D leaders gathered in Shanghai to discuss the future of the pharmaceutical industry

Renamed Nastech Turns To RNAi

Company to divest intranasal program rather than spin out.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts